MULTI-CENTER TRIAL SHOWS SIGNIFICANT PAIN RELIEF FOR SPINE CANCER PATIENTS FOLLOWING TARGETED RADIOFREQUENCY ABLATION TREATMENT
SAN JOSE, Calif. – July 21, 2014 - DFINE®, Inc., a market leader in the minimally
invasive treatment of spinal diseases, today announced the publication of a multi-center
study in the July/August issue of Pain Physician Journal
, the official peer-reviewed
publication of the American Society of Interventional Pain Physicians (ASIPP).
DFINE ANNOUNCES COMMENCEMENT OF CLINICAL STUDY ON SPINAL TUMOR ABLATION WITH THE STAR TUMOR ABLATION SYSTEM
San Jose, Calif. and Magdeburg, Germany – June 11, 2014 - DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced that the first patient has been enrolled in the EU-STAR Clinical Trial. The multi-center trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with the STAR™ Tumor Ablation System for the palliative treatment of metastatic spinal tumors.
NEW ONLINE RESOURCE FOR PATIENTS WITH PAINFUL SPINAL TUMORS
San Jose, Calif. – March 18, 2014 – DFINE®, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the launch of www.spine-tumors.com, a new online resource created to educate patients about a minimally-invasive treatment option for severe pain due to metastatic spinal tumors.
NEW STUDIES HIGHLIGHT BENEFITS OF STAR TUMOR ABLATION SYSTEM FOR PATIENTS WITH SPINAL TUMORS
San Jose, Calif. – Feb. 18, 2014 –Two studies presented at the American Society of Spine Radiology (ASSR) 2014 Annual Symposium in Miami highlighted the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the DFINE STAR™ Tumor Ablation System. The studies demonstrated the ability of the STAR System to provide significant pain relief to patients suffering from painful spinal metatases; in many cases, these patients had not responded to standard therapies, such as radiation or chemotherapy.